Marie-France Nguyen1, Marc Bonnefoy1,2, Arnaud Adrait1, Marine Gueugnon3, Charles Petitot1, Lionel Collet4, Adeline Roux3, Xavier Perrot2,4,5. 1. Geriatric Medicine Unit, Lyon Sud Hospital, Hospices Civils de Lyon, Pierre Bénite, France. 2. University Claude Bernard Lyon 1, Faculty of Medicine Lyon Sud, Pierre Bénite, France. 3. Clinical Research Unit, Pole IMER, Hospices Civils de Lyon, Lyon, France. 4. Department of Audiology, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France. 5. Institute of Sciences and Techniques for Rehabilitation (ISTR), Lyon 1 University, University of Lyon, Lyon, France.
Abstract
BACKGROUND/ OBJECTIVE: This study evaluated the cognitive benefit of hearing aids (HA) in older patients with Alzheimer's disease (AD) and hearing loss (HL) after a 6- and 12-month period of utilization. METHODS: A multicenter double-blind randomized placebo-controlled trial was conducted in patients aged more than 65 years. A group was equipped with active HA for 6 months (active group) and a second group had placebo HA for 6 months (placebo group) followed by a secondary activation phase for a further 6 months (semi crossover procedure). Both groups were retested after a 12-month period. The primary endpoint was the change from baseline of the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS Cog) after a 6-month period in both groups and after 6 months of secondary HA activation in the placebo group. A smaller cognitive decline should be obtained with HA use; an increase in ADAS Cog score of less than 6 points was defined a success. RESULTS:Fifty-one patients aged 68 to 99 years were included; 38 attended the 6-month visit: 18 in the active group and 20 in the placebo group. At 6 months, 14 (82.4%) successes were noticed in the active group, and 15 (88.2%) in the placebo group (p = 1.0); delta ADAS Cog in the active group was 1.8±5.3 and 1.3±5.3 in the placebo group (p = 0.8). In the placebo group, after the secondary HA activation, no significant improvement was observed. CONCLUSION: No significant effect of HA use was observed after 6 months of follow-up in patients with AD and HL.
RCT Entities:
BACKGROUND/ OBJECTIVE: This study evaluated the cognitive benefit of hearing aids (HA) in older patients with Alzheimer's disease (AD) and hearing loss (HL) after a 6- and 12-month period of utilization. METHODS: A multicenter double-blind randomized placebo-controlled trial was conducted in patients aged more than 65 years. A group was equipped with active HA for 6 months (active group) and a second group had placebo HA for 6 months (placebo group) followed by a secondary activation phase for a further 6 months (semi crossover procedure). Both groups were retested after a 12-month period. The primary endpoint was the change from baseline of the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS Cog) after a 6-month period in both groups and after 6 months of secondary HA activation in the placebo group. A smaller cognitive decline should be obtained with HA use; an increase in ADAS Cog score of less than 6 points was defined a success. RESULTS: Fifty-one patients aged 68 to 99 years were included; 38 attended the 6-month visit: 18 in the active group and 20 in the placebo group. At 6 months, 14 (82.4%) successes were noticed in the active group, and 15 (88.2%) in the placebo group (p = 1.0); delta ADAS Cog in the active group was 1.8±5.3 and 1.3±5.3 in the placebo group (p = 0.8). In the placebo group, after the secondary HA activation, no significant improvement was observed. CONCLUSION: No significant effect of HA use was observed after 6 months of follow-up in patients with AD and HL.
Authors: Sara K Mamo; Nicholas S Reed; Carrie Price; Dona Occhipinti; Alexandra Pletnikova; Frank R Lin; Esther S Oh Journal: J Speech Lang Hear Res Date: 2018-10-26 Impact factor: 2.297
Authors: Fiona Höbler; Katherine S McGilton; Walter Wittich; Kate Dupuis; Marilyn Reed; Shirley Dumassais; Paul Mick; M Kathleen Pichora-Fuller Journal: J Alzheimers Dis Date: 2021 Impact factor: 4.472